The DTRF advocates for almost a decade for clinical trials in the promising desmoid tumor treatment nirogacestat. After a successful Phase 3 trial, Springworks Therapeutics files a new drug application. If approved by the FDA, this will be the first drug approved in desmoid tumors! The trial is published in the NEJM.
by
